11 news items
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
ZLAB
20 May 24
diarrhea to fatal colitis. Evaluate if diarrhea occurs. If CDAD is suspected or confirmed, the risk/benefit of continuing treatment with XACDURO
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA
ZLAB
12 May 24
. There is a significant unmet need for these patients given the limited durability of benefit due to the emergence of resistance with existing therapies
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
CRDF
JNJ
NTBL
9 May 24
-based treatment to benefit pancreatic cancer patients," said Thomas Heineman , M.D
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
ZLAB
2 Apr 24
clinical trials, the potential benefits of ZL-1310 and ZL-1218, and the potential treatment of SCLC and other solid tumors. These forward-looking statements
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
BMY
ZLAB
1 Apr 24
demonstrated a statistically significant and clinically meaningful benefit in PFS and ORR compared to standard-of-care chemotherapy as a second-line
yh20u9c457bl4ylt9zrxfcn1m6jqfp4pxf328dulzo r9y
NVCR
ZLAB
27 Mar 24
prospects and plans for developing and commercializing TTFields, the potential benefits of TTFields, and the potential treatment for patients with brain
v9hafbeb3jjzs4xv1t87ov4ocyvl3vq1ynzxkwsmud6uhprd6fw280eret
ZLAB
13 Mar 24
.1 More than 88% of SCLC patients overexpress DLL3 and could benefit from targeted therapeutic agents
4bdjogtagrcetsl0qyqduma8uyc4eu3 84
ZLAB
6 Mar 24
progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized
p6rvkyhqly45fmh2pdrg59ix7g0gfh 7zh7rkgjdwlk4
ZLAB
6 Mar 24
.
"Previous progression-free survival and interim OS data from the NORA study demonstrated the benefit of niraparib maintenance therapy with an individualized
3bemrhsbl ikwsjjcklzwq7e0ymxrhcg51el0low
ZLAB
27 Feb 24
discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product
o1jorue0
BILI
SDGR
ZH
25 Feb 24
our mission of promoting sustainable growth and creating positive social impact."
Benefiting from
- Prev
- 1
- Next